Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Vismodegib in locally advanced basal cell carcinoma in Slovenia
Authors:ID Mesti, Tanja (Author)
ID Sever, Maša (Author)
ID Ocvirk, Janja (Author)
Files:.pdf PDF - Presentation file, download (448,27 KB)
MD5: 66E91885F3EF84346935C832F834BC41
 
URL URL - Source URL, visit https://www.karger.com/Article/Pdf/525612
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz syndrome [G-G Syn]) treated with vismodegib in routine clinical practice in Slovenia in 8.3-year period. Methods: In this retrospective cohort study, we analyzed baseline characteristics, outcomes, and treatment-related adverse events from locally advanced BCC. The patients were divided into two cohorts: 39 laBCC or multiple BCC patients and 7 patients with G-G Syn who were treated with vismodegib from November 2012 till January 2021. Results: During 100-month period, 46 patients were diagnosed with laBCC (26), multiple BCC (13), and G-G Syn (7), all inappropriate for surgery or radiotherapy. Baseline characteristics: median age was 72.8 years in laBCC + multiple BCC cohort and 47.4 years in G-G Syn cohort. The objective response rate was 80% in laBCC + multiple BCC and 86% in G-G Syn cohort. Disease control rate (DCR) was 95% in laBCC + multiple BCC and 100% in G-G Syn cohort. Median duration of treatment was 9.9 months (range: 1.5-43.1) in laBCC and multiple BCC cohort and 19.5 months (range: 3.6-94.1) in G-G Syn cohort. Majority of treatment-emergent adverse events (TEAEs) in laBCC or multiple BCC cohort were grade 1 or 2 (96%), only 4% of AEs were grade 3. Majority of TEAEs in G-G Syn cohort were also grade 1 or 2 (87%), 13% of AEs were grade 3. No grade 4 or 5 vismodegib-related AEs were reported. Conclusion: Vismodegib has shown meaningful efficacy with DCR from 95% to 100% in patients with laBCC, multiple BCC, and G-G Syn in Slovenia. TEAEs were successfully alleviated with multidisciplinary approach and early supportive care.
Keywords:basal cell carcinoma, early supportive care, Gorlin Goltz syndrome, multidisciplinary approach
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2022
Publisher:S. Karger
Year of publishing:2022
Number of pages:str. 1-7
Numbering:Vol. , no.
PID:20.500.12556/DiRROS-15459 New window
UDC:616.5
ISSN on article:1018-8665
DOI:10.1159/000525612 New window
COBISS.SI-ID:117583107 New window
Copyright:by Authors
Publication date in DiRROS:07.09.2022
Views:785
Downloads:429
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Dermatology
Shortened title:Dermatology
Publisher:S.Karger
ISSN:1018-8665
COBISS.SI-ID:748308 New window

Document is financed by a project

Funder:ARRS - Slovenian Research Agency
Project number:P3-0321-2020
Name:Napovedni dejavniki poteka bolezni in odgovora na zdravljenje pri različnih vrst raka

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:07.09.2022

Secondary language

Language:Slovenian
Keywords:bazalnocelični rak, sindrom Gorlin Goltz, večdisciplinarni pristop


Back